Canaccord Genuity Maintains Buy on Travere Therapeutics, Raises Price Target to $56

Canaccord Genuity analyst Edward Nash maintains Travere Therapeutics (NASDAQ:TVTX) with a Buy and raises the price target from $47 to $56.